Free tool · No account
Clinical trials for bladder cancer
Bladder cancer trials differ between early, non-muscle-invasive disease and advanced disease, with immunotherapy and antibody-drug conjugates prominent in the advanced setting.
505 recruiting trials. Showing a sample.
- recruitingNCT05792033
Multicentric Prospective T1 Urinary Bladder Cancer Registry
Synopsis Rationale Patients with T1 urinary bladder cancer (UBC) are at high risk for recurrence and progression. However, the prognosis is dependent on several concomitant factors. First and foremost, an accurate diagnosis is imperative for an appropriate disease management. ...
Listed by the study for T1 Urinary Bladder Cancer. Record updated 2023-04-04.
Sponsored by Medical University of ViennaFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06257017
Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma
Urothelial carcinomas are one of the most commonly diagnosed cancers worldwide. Postoperative patients carry a poor prognosis with an estimated five-year disease-specific survival rate of 50%. To improve overall survival and reduce the recurrent risk, chemotherapy is recommend...
Listed by the study for Muscle Invasive Bladder Urothelial Carcinoma. Record updated 2025-04-04.
Sponsored by Yung NAFull details on ClinicalTrials.gov → - recruitingNCT05337397
Outpatient Laser Ablation of Recurrent Non-muscle Invasive Bladder Cancer
Aim: To investigate the feasibility and tolerability of the Olympus Soltive laser in treatment of large recurrent low-grade Ta tumours in an outpatient setting. Background: Non-muscle invasive bladder cancer (NMIBC) is associated with a high yearly recurrence rate up to to 61...
Listed by the study for Non-Muscle Invasive Bladder Cancer. Record updated 2022-08-08.
Sponsored by Jørgen Bjerggaard JensenFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researcher...
Listed by the study for Urinary Bladder Neoplasms. Record updated 2026-09-03.
Sponsored by BayerFull details on ClinicalTrials.gov → - recruitingPhase 3NCT06196736
A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer
The purpose of this study was to compare the antitumor activity of 9MW2821 and chemotherapy in participants with locally advanced or metastatic urothelial cancer previously treated with PD-(L)1 inhibitor and platinum-containing chemotherapy.
Listed by the study for Advanced Urothelial Carcinoma. Record updated 2025-04-13.
Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.Full details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340...
Listed by the study for Urothelial Carcinoma. Record updated 2026-08-17.
Sponsored by Bristol-Myers SquibbFull details on ClinicalTrials.gov → - recruitingNANCT04693377
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with pain from cancer that has spread to the bones (bone metastases). Bone is a common site of metasta...
Listed by the study for Metastatic Urothelial Carcinoma. Record updated 2026-04-15.
Sponsored by M.D. Anderson Cancer CenterFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT07579195
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
This pilot feasibility clinical trial is evaluating a novel treatment strategy for patients with advanced bladder cancer that is unresectable, has spread to nearby lymph nodes or a limited number of distant sites (oligometastatic disease), and has responded to initial treatmen...
Listed by the study for Muscle Invasive Bladder Carcinoma. Record updated 2026-08-25.
Sponsored by University of WashingtonFull details on ClinicalTrials.gov → - recruitingNCT07756437
Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer
This prospective observational study evaluates a blood-based circulating tumor DNA (ctDNA) test in patients with muscle-invasive bladder cancer or upper tract urothelial cancer. ctDNA consists of small fragments of tumor DNA that can sometimes be detected in the blood. In thi...
Listed by the study for Muscle-Invasive Bladder Cancer (MIBC). Record updated 2026-08-10.
Sponsored by AZ Sint-Lucas GentFull details on ClinicalTrials.gov → - recruitingNCT06447064
Cancer Loyalty Card Study 2 (CLOCS-2)
Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and treated early. Delay in cancer diagnosis can occur at any point along the diagnostic spe...
Listed by the study for Bladder Cancer. Record updated 2026-03-25.
Sponsored by Imperial College LondonFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-09-16. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this bladder cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.